Cadila Healthcare gains after USFDA nod for Imatinib Mesylate tablets

Cadila Healthcare rose 1.76% to Rs 356.10 after the company said it received final approval from the US drug regulator for Imatinib Mesylate tablets.

The company announced during trading hours today, 9 April 2020, that Zydus Cadila has received final approval from the US Food and Drug Administration (USFDA) to market Imatinib Mesylate tablets, 100 mg and 400 mg. (US RLD: Gleevec Tablets). This medication is used to treat certain types of leukemia (blood cancer), bone marrow disorders, skin cancer and tumors of the stomach and digestive system. The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, in Ahmedabad.

The group now has 285 approvals and has so far filed over 386 ANDAs since the commencement of the filing process in FY 2003-04.

On 7 April 2020, Cadila Healthcare received final approval from the US drug regulator to market Perphenazine tablets in multiple strengths. This medication is indicated for the treatment of schizophrenia and for the control of severe nausea and vomiting in adults. The drug will be manufactured at the group's formulation manufacturing facility at Baddi, Himachal Pradesh.

The company on 2 April 2020, received the final approval from USFDA to market Lamotrigine extended-release tablets USP in multiple strengths of 25 mg, 50 mg, 100 mg, 200 mg, 250 mg, and 300 mg. The medication is indicated for treating certain types of seizures. It will be manufactured at the group manufacturing facility at SEZ, Ahmedabad in Gujarat.

On a consolidated basis, the drug maker's net profit fell 26.54% to Rs 375.18 crore on a 0.52% increase in net sales to Rs 3,534.50 crore in Q3 December 2019 Q3 December 2018.

Cadila Healthcare is a pharmaceutical company based in India.

Powered by Capital Market - Live News